Unravelling sex-specific differences in autosomal dominant polycystic kidney disease: a multiorgan perspective
Open Access
- 21 November 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (1)
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a complex, multisystemic disorder exhibiting notable sex-related differences in clinical presentation, progression and complications. While the disease affects both sexes, disease expression and complications differ significantly between men and women. This review explores the biological, hormonal and psychosocial sex differences in ADPKD across multiple clinical domains. Men tend to experience faster kidney growth, earlier onset of hypertension and slightly younger age at kidney replacement therapy. Women, in contrast, are more susceptible to polycystic liver disease (PLD), often exacerbated by oestrogen exposure, especially during pregnancy or hormonal treatments. Although urinary tract infections are more prevalent among women, cyst infections show no major sex-based difference in incidence, although men may respond less favourably to antibiotic therapy. Cardiovascular complications, intracranial aneurysms and reproductive health risks also show sex-related patterns. Fertility and reproductive counselling must be individualized, as reproductive challenges and risks differ markedly between men and women. Pregnancy in women with ADPKD, especially those with reduced renal function or PLD, carries increased risks and requires specialized care. Fertility in men with ADPKD is usually preserved, although sometimes it may be impaired due to seminal vesicle cysts and sperm morphological abnormalities. However, assisted reproductive techniques generally achieve outcomes comparable to those of unaffected individuals. Psychosocial aspects such as pain, emotional burden and quality of life are also influenced by sex and require integrated management strategies. While tolvaptan slows disease progression in both sexes, pharmacodynamic responses may differ slightly. Incorporating sex-specific insights into ADPKD care, including hormonal and reproductive considerations, is critical to advancing personalized medicine. Understanding these differences will optimize management and improve quality of life for individuals living with ADPKD.Keywords
Funding Information
- Instituto de Salud Carlos III (PI22/00361)
- Instituto de Salud Carlos III (PI24/00823)
- Instituto de Salud Carlos III (AC23_2/00043)
- European Union (RD24/0004/002)
This publication has 150 references indexed in Scilit:
- Exome Sequencing of a Clinical Population for Autosomal Dominant Polycystic Kidney DiseaseJAMA, 2022
- Gender Differences in Liver Transplantation Outcomes in Polycystic Liver DiseaseDigestive Diseases and Sciences, 2021
- Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issuesClinical and Experimental Nephrology, 2020
- Estrogen‐Containing Oral Contraceptives Are Associated With Polycystic Liver Disease Severity in Premenopausal PatientsClinical Pharmacology & Therapeutics, 2019
- Multiple urinary tract infections are associated with genotype and phenotype in adult polycystic kidney diseaseClinical and Experimental Nephrology, 2019
- Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventionsJournal of Cellular Physiology, 2019
- Relationship between intracranial aneurysms and the severity of autosomal dominant polycystic kidney diseaseActa Neurochirurgica, 2017
- Autosomal dominant polycystic kidney disease: Comprehensive mutation analysis of PKD1 and PKD2 in 700 unrelated patientsHuman Mutation, 2012
- Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney diseaseHepatology, 1997
- Risk Factors for the Development of Hepatic Cysts in Autosomal Dominant Polycystic Kidney DiseaseHepatology, 1990